Angle PLC Announces Change of Adviser
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
RBI Data Reveals Divergence in Credit Card Spending and Debit Card Cash Withdrawals
-
First-time boat buyers advised to assess full ownership costs
-
Panthers expected to begin 2027 NRL season away from new stadium
-
Planning and preparation can reduce stress of interstate relocation
-
Sweet As app launches restaurant discovery platform
-
Two more arrested in Carrie Mullane suspected murder investigation
-
Phoenix Restaurants Offer Thanksgiving Dinner to Go for Pickup
-
MLA seeks inquiry into reported sectarian gestures on Ormeau Road
-
Mayo school appeals for information after convent and chapel vandalism
-
Louise O’Reilly attacks Simon Harris over unemployment remarks
-
Virginia overwhelms Arkansas 91-72 behind balanced scoring
-
Canadian soldier Aidan Goulding remembered at Vancouver funeral
-
Second major storm brings destructive winds and outages to British Columbia
-
Tayyab Arif hits 57 on Pakistan Test debut against Sri Lanka
-
Godzilla Minus Zero leads North American box office with $31.6m
-
Robert Trujillo discusses literacy and social justice children’s books
-
Advocate calls for coordinated support for children facing trafficking
-
Civil rights advocate William Bill Tucker dies aged 98
-
Medicare Open Enrollment Ends Dec. 7: Review Your Coverage Options
-
Pennsylvania Democrats secure state trifecta in midterm elections
-
US Treasury order targets bank transfers linked to crypto exchange MEXC
-
Godzilla Minus Zero sets foreign-language box-office opening record
-
Nvidia CEO Controversy Sparks Fears of Tighter U.S. AI Chip Curbs for Samsung and SK hynix
-
Eagles record six sacks as rushing attack struggles against Giants
-
Villeneuve teases James Bond casting at Los Angeles museum gala
-
Thames Water seeks to delay £12bn in debt repayments
-
Nottinghamshire launches specialist rural crime policing team
-
Newark boxing gym expands alternative education programme
-
China confirms talks over possible Xi-Putin-Trump summit
-
Democrats consider impeachment drive against Defence Secretary Hegseth
-
Rail journey offers a slower route to a Berlin city break
-
Energy bill plan could use HMRC income data to target support
-
Arsenal control title race as Manchester United fall into bottom three
-
Business owner earning £6,000 a month tackles £70,000 debt
-
Suspected Krakow gunman dies after attack that killed six
-
Nvidia chief faces inquiry after disclosing affair with suspected Chinese agent
-
Carrick backs Dalot after hostile reception from Manchester United fans
-
Comet returns as online electrical marketplace 14 years after collapse
-
Aston Villa Defy History With Rare Victory at Old Trafford
Angle PLC Announces Change of Adviser
APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER
APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER
GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has appointed Cavendish Capital Markets Limited as the Company's Nominated Adviser and Sole Broker with immediate effect.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Cavendish (NOMAD and Broker) | +44 (0) 20 7220 0500 |
FTI Consulting |
|
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 115 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
